Mass information on charge variants is changing the game

Join the discussion on strategies to address characterization of protein therapeutics at the intact level during process development. Learn how an integrated icIEF-UV/MS workflow on the Intabio ZT system is changing the game for intact protein analysis.

Register Free: https://www.biopharminternational.com/bp_w/charge-variants

Event Overview:

In the development of biotherapeutics, genetic variations and post-translational modifications give each molecule a "personality”. Understanding these unique characteristics drives the development, manufacturability, and analytical methods used to monitor and control the quality attributes and testing requirements.

Join the discussion on strategies to address characterization of protein therapeutics at the intact level during process development. Learn more about the challenges in charge heterogeneity profiling, and how a disruptive approach using an integrated icIEF-UV/MS workflow with the Intabio ZT system is changing the game for scientists pushing the next generation of biotherapeutics forward.

Key Learning Objectives:
A disruptive approach for characterization of mAb charge variants in biopharmaceutical process development by icIEF-UV/MS

• Learn how a new strategy can make a difference in assessing the impact cell culture conditions have on mAb quality and production.

Intact-level multi-attribute monitoring of complex biologics

• Explore the potential of using icIEF-UV/MS for characterizing PQAs of complex biotherapeutics, including mAbs, ADCs and complex Fc fusion proteins.

Characterization of a biopharmaceutical intensified process utilizing icIEF-UV/MS to quantify advanced glycation end products as a source of color

• Probe the cause of color change in protein therapeutics and learn how a cell line development group is utilizing the integrated icIEF-UV/MS workflow to monitor these advanced glycation events for product release

Who Should Attend:

• Scientists in drug discovery, cell line development and protein therapeutics characterization

Speakers:

Greg Adams PhD
Sr. Director Global Analytical Strategy & Development
FujiFilm Diosynth Biotechnologies

Anita P. Liu PhD
Associate Principal Scientist
Merck

Kristen Nields PhD
Senior Scientist
Janssen

Register Free: https://www.biopharminternational.com/bp_w/charge-variants